Personalized cancer chemotherapy: efficacy and safety based on pharmacokinetics and pharmacogenetics

2015 Fiscal Year Final Research Report

• Project/Area Number: 25460202
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: National Cancer Center Japan
• Principal Investigator: Hamada Akinobu 国立研究開発法人国立がん研究センター, その他部局等, 分野長 (00322313)
• Co-Investigator(Kenkyū-buntansha): TAMURA Kenji 国立研究開発法人国立がん研究センター, 中央病院, 科長 (60340783) ; FUJIWARA Yutaka 国立研究開発法人国立がん研究センター, 中央病院, 医長 (70464261)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 薬物動態 / 個別化医療 / ABCB1 / クリゾチニブ / エリブリン

Outline of Final Research Achievements

In 78 non-small cell lung cancer (ALK fusion gene-positive) patients treated with crizotinib, the trough plasma concentration of crizotinib did not correlate the development of liver dysfunction and QT prolongation. On the other hand, the association of ABCB1 1236TT-2677TT-3435TT genotype with crizotinib pharamcokinetics was observed.
In 29 inoperable or recurrent breast cancer patient treated with eribulin the results of interim analysis suggest that the development of over grade 3 myelosuppression may be associated with the plasma concentration of eribulin after 24 hour administration.

Free Research Field

臨床薬理学